Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial
Neisseria meningitidis outer membrane vesicle (OMV) vaccines are safe and provide strain-specific protection against invasive meningococcal disease (IMD) primarily by inducing serum bactericidal antibodies against the outer membrane proteins (OMP). To design broader coverage vaccines, knowledge of t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2022
|
| _version_ | 1797088608677527552 |
|---|---|
| author | Rollier, CS Dold, C Marsay, L Linder, A Green, CA Sadarangani, M Norheim, G Derrick, JP Feavers, IM Maiden, M Pollard, AJ |
| author_facet | Rollier, CS Dold, C Marsay, L Linder, A Green, CA Sadarangani, M Norheim, G Derrick, JP Feavers, IM Maiden, M Pollard, AJ |
| author_sort | Rollier, CS |
| collection | OXFORD |
| description | Neisseria meningitidis outer membrane vesicle (OMV) vaccines are safe and provide strain-specific protection against invasive meningococcal disease (IMD) primarily by inducing serum bactericidal antibodies against the outer membrane proteins (OMP). To design broader coverage vaccines, knowledge of the immunogenicity of all the antigens contained in OMVs is needed. In a Phase I clinical trial, an investigational meningococcal OMV vaccine, MenPF1, made from a meningococcus genetically modified to constitutively express the iron-regulated FetA induced bactericidal responses to both the PorA and the FetA antigen present in the OMP. Using peripheral blood mononuclear cells collected from this trial, we analyzed the kinetics of and relationships between IgG, IgA, and IgM B cell responses against recombinant PorA and FetA, including (i) antibody-secreting cells, (ii) memory B cells, and (iii) functional antibody responses (opsonophagocytic and bactericidal activities). Following MenPF1vaccination, PorA-specific IgG secreting cell responses were detected in up to 77% of participants and FetA-specific responses in up to 36%. Memory B cell responses to the vaccine were low or absent and mainly detected in participants who had evidence of preexisting immunity (P = 0.0069). Similarly, FetA-specific antibody titers and bactericidal activity increased in participants with preexisting immunity and is consistent with the idea that immune responses are elicited to minor antigens during asymptomatic Neisseria carriage, which can be boosted by OMV vaccines.
|
| first_indexed | 2024-03-07T02:52:32Z |
| format | Journal article |
| id | oxford-uuid:ae299745-7752-498a-ab96-50f6aabcf124 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:52:32Z |
| publishDate | 2022 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:ae299745-7752-498a-ab96-50f6aabcf1242022-03-27T03:40:50ZHuman B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ae299745-7752-498a-ab96-50f6aabcf124EnglishSymplectic ElementsAmerican Society for Microbiology2022Rollier, CSDold, CMarsay, LLinder, AGreen, CASadarangani, MNorheim, GDerrick, JPFeavers, IMMaiden, MPollard, AJNeisseria meningitidis outer membrane vesicle (OMV) vaccines are safe and provide strain-specific protection against invasive meningococcal disease (IMD) primarily by inducing serum bactericidal antibodies against the outer membrane proteins (OMP). To design broader coverage vaccines, knowledge of the immunogenicity of all the antigens contained in OMVs is needed. In a Phase I clinical trial, an investigational meningococcal OMV vaccine, MenPF1, made from a meningococcus genetically modified to constitutively express the iron-regulated FetA induced bactericidal responses to both the PorA and the FetA antigen present in the OMP. Using peripheral blood mononuclear cells collected from this trial, we analyzed the kinetics of and relationships between IgG, IgA, and IgM B cell responses against recombinant PorA and FetA, including (i) antibody-secreting cells, (ii) memory B cells, and (iii) functional antibody responses (opsonophagocytic and bactericidal activities). Following MenPF1vaccination, PorA-specific IgG secreting cell responses were detected in up to 77% of participants and FetA-specific responses in up to 36%. Memory B cell responses to the vaccine were low or absent and mainly detected in participants who had evidence of preexisting immunity (P = 0.0069). Similarly, FetA-specific antibody titers and bactericidal activity increased in participants with preexisting immunity and is consistent with the idea that immune responses are elicited to minor antigens during asymptomatic Neisseria carriage, which can be boosted by OMV vaccines. |
| spellingShingle | Rollier, CS Dold, C Marsay, L Linder, A Green, CA Sadarangani, M Norheim, G Derrick, JP Feavers, IM Maiden, M Pollard, AJ Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title | Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title_full | Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title_fullStr | Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title_full_unstemmed | Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title_short | Human B cell responses to dominant and sub-dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase I trial |
| title_sort | human b cell responses to dominant and sub dominant antigens induced by a meningococcal outer membrane vesicle vaccine in a phase i trial |
| work_keys_str_mv | AT rolliercs humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT doldc humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT marsayl humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT lindera humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT greenca humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT sadaranganim humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT norheimg humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT derrickjp humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT feaversim humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT maidenm humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial AT pollardaj humanbcellresponsestodominantandsubdominantantigensinducedbyameningococcaloutermembranevesiclevaccineinaphaseitrial |